JP2019534308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534308A5 JP2019534308A5 JP2019524428A JP2019524428A JP2019534308A5 JP 2019534308 A5 JP2019534308 A5 JP 2019534308A5 JP 2019524428 A JP2019524428 A JP 2019524428A JP 2019524428 A JP2019524428 A JP 2019524428A JP 2019534308 A5 JP2019534308 A5 JP 2019534308A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- acting
- cancer
- long
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims description 77
- 239000000556 agonist Substances 0.000 claims description 75
- 206010028980 Neoplasm Diseases 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 16
- 210000003289 regulatory T cell Anatomy 0.000 claims description 11
- 238000009825 accumulation Methods 0.000 claims description 8
- 229940022399 cancer vaccine Drugs 0.000 claims description 8
- 238000009566 cancer vaccine Methods 0.000 claims description 8
- 238000010172 mouse model Methods 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 229940124753 IL-2 agonist Drugs 0.000 claims description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 108700025316 aldesleukin Proteins 0.000 claims description 4
- 229960005310 aldesleukin Drugs 0.000 claims description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 108010041986 DNA Vaccines Proteins 0.000 claims description 2
- 229940021995 DNA vaccine Drugs 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 201000002454 adrenal cortex cancer Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 229940037642 autologous vaccine Drugs 0.000 claims description 2
- 210000000013 bile duct Anatomy 0.000 claims description 2
- 229940030156 cell vaccine Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims description 2
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 2
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 13
- 230000004913 activation Effects 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662420442P | 2016-11-10 | 2016-11-10 | |
| US62/420,442 | 2016-11-10 | ||
| US201762582852P | 2017-11-07 | 2017-11-07 | |
| US62/582,852 | 2017-11-07 | ||
| PCT/US2017/060911 WO2018089669A2 (en) | 2016-11-10 | 2017-11-09 | Immunotherapeutic tumor treatment method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534308A JP2019534308A (ja) | 2019-11-28 |
| JP2019534308A5 true JP2019534308A5 (enExample) | 2020-12-17 |
Family
ID=62110016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524428A Pending JP2019534308A (ja) | 2016-11-10 | 2017-11-09 | 免疫療法的腫瘍治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190275133A1 (enExample) |
| EP (1) | EP3538130A4 (enExample) |
| JP (1) | JP2019534308A (enExample) |
| KR (1) | KR20190105568A (enExample) |
| CN (1) | CN109890406A (enExample) |
| AU (1) | AU2017357042A1 (enExample) |
| CA (1) | CA3043597A1 (enExample) |
| IL (1) | IL266511A (enExample) |
| MA (1) | MA46771A (enExample) |
| MX (1) | MX2019005465A (enExample) |
| WO (1) | WO2018089669A2 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| WO2019094396A1 (en) * | 2017-11-07 | 2019-05-16 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP3930747A4 (en) * | 2019-02-27 | 2023-04-05 | Nektar Therapeutics | IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER |
| CN113795271A (zh) * | 2019-03-08 | 2021-12-14 | 森德治疗公司 | 与irgd共施用以治疗癌症的低剂量细胞因子 |
| US12351653B1 (en) | 2019-03-08 | 2025-07-08 | Lisata Therapeutics, Inc. | Pharmaceutical compositions comprising novel cyclic peptides |
| CA3141327A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
| JP2023514010A (ja) | 2020-01-10 | 2023-04-05 | ブライト ピーク セラピューティクス エージー | 修飾ｉｌ－２ポリペプチドおよびその使用 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| JP2023524639A (ja) | 2020-04-22 | 2023-06-13 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 患者特異的免疫療法用細胞の製造調整システム及び調整方法 |
| CA3176826A1 (en) | 2020-05-04 | 2021-11-11 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| EP4146793A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| WO2022010928A1 (en) * | 2020-07-06 | 2022-01-13 | Nektar Therapeutics (India) Pvt. Ltd. | Method for enhancing humoral immunity |
| EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CA3201818A1 (en) | 2020-12-11 | 2022-06-16 | Maria Fardis | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| CA3202483A1 (en) | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| CA3203382A1 (en) | 2020-12-31 | 2022-07-07 | Adrian Emanual Wells | Devices and processes for automated production of tumor infiltrating lymphocytes |
| WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| CN117279506A (zh) | 2021-03-05 | 2023-12-22 | 艾欧凡斯生物治疗公司 | 肿瘤储存及细胞培养组合物 |
| JP2024510505A (ja) | 2021-03-19 | 2024-03-07 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｃｄ３９／ｃｄ６９選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張及びｔｉｌにおける遺伝子ノックアウトのための方法 |
| KR20240037185A (ko) | 2021-04-19 | 2024-03-21 | 이오반스 바이오테라퓨틱스, 인크. | 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도 |
| JP2024519029A (ja) | 2021-05-17 | 2024-05-08 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用 |
| JP2024526898A (ja) | 2021-07-22 | 2024-07-19 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 固形腫瘍断片の凍結保存のための方法 |
| WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
| CA3235824A1 (en) | 2021-10-27 | 2023-05-04 | Frederick G. Vogt | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| US20250032618A1 (en) | 2021-11-10 | 2025-01-30 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| US20250101380A1 (en) | 2022-01-28 | 2025-03-27 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| CA3247638A1 (en) | 2022-04-06 | 2023-10-12 | Maria Fardis | TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA (NSCLC) WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES |
| WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| US20250281537A1 (en) | 2022-05-10 | 2025-09-11 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
| WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| JP2025531877A (ja) | 2022-09-09 | 2025-09-25 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス |
| WO2024055018A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| EP4612277A1 (en) | 2022-11-04 | 2025-09-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| KR20250122544A (ko) | 2022-11-21 | 2025-08-13 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법 |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| EP4743565A2 (en) | 2023-07-13 | 2026-05-20 | Iovance Biotherapeutics Inc | Lentiviral vectors encoding cytokines and their uses in the production of tumor-infiltrating lymphocytes |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| WO2025171182A1 (en) | 2024-02-08 | 2025-08-14 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine |
| WO2026006784A1 (en) | 2024-06-28 | 2026-01-02 | Iovance Biotherapeutics, Inc. | Methods of making tumor reactive peripheral blood lymphocytes (trpbl) |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
| WO2026072794A2 (en) | 2024-09-26 | 2026-04-02 | Iovance Biotherapeutics, Inc. | Expansion processes for til product enriched with neoantigen- reactive t cells (narts) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5290551A (en) * | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
| CN101573139A (zh) * | 2006-02-16 | 2009-11-04 | 纳森特生物制剂公司 | 在哺乳动物个体中改善免疫功能的方法以及预防或治疗疾病的方法 |
| KR102591732B1 (ko) * | 2010-11-12 | 2023-10-19 | 넥타르 테라퓨틱스 | Ｉｌ-2 부분 및 중합체의 접합체 |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| AU2012371610A1 (en) * | 2012-03-02 | 2014-10-02 | Providence Health & Services - Oregon | Dual OX40 agonist/IL-2 cancer therapy methods |
| US20150017120A1 (en) * | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| EP3834838A1 (en) * | 2014-02-21 | 2021-06-16 | Nektar Therapeutics (India) Pvt. Ltd. | Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody |
| WO2016025647A1 (en) * | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
-
2017
- 2017-11-09 WO PCT/US2017/060911 patent/WO2018089669A2/en not_active Ceased
- 2017-11-09 KR KR1020197015656A patent/KR20190105568A/ko not_active Ceased
- 2017-11-09 JP JP2019524428A patent/JP2019534308A/ja active Pending
- 2017-11-09 CN CN201780067219.5A patent/CN109890406A/zh active Pending
- 2017-11-09 AU AU2017357042A patent/AU2017357042A1/en not_active Abandoned
- 2017-11-09 MA MA046771A patent/MA46771A/fr unknown
- 2017-11-09 CA CA3043597A patent/CA3043597A1/en not_active Abandoned
- 2017-11-09 US US16/349,227 patent/US20190275133A1/en not_active Abandoned
- 2017-11-09 MX MX2019005465A patent/MX2019005465A/es unknown
- 2017-11-09 EP EP17870172.8A patent/EP3538130A4/en not_active Withdrawn
-
2019
- 2019-05-07 IL IL266511A patent/IL266511A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Phuengkham et al. | A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy | |
| Sun et al. | ATP‐responsive smart hydrogel releasing immune adjuvant synchronized with repeated chemotherapy or radiotherapy to boost antitumor immunity | |
| ES2609767T3 (es) | Combinaciones de un inhibidor de PI3K y un inhibidor de MEK | |
| JP2019532080A5 (enExample) | ||
| JP2020509018A5 (enExample) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| Wu et al. | In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma | |
| JP2013501731A5 (enExample) | ||
| MX2024008496A (es) | Uso de un antisentido para la preparacion de un medicamento para tratar canceres. | |
| JPWO2016204193A1 (ja) | 抗がん剤 | |
| Chen et al. | Well-established immunotherapy with R837-loaded boron neutron capture-shocked tumor cells | |
| JP2015516496A5 (enExample) | ||
| JP5952890B2 (ja) | 膵臓癌を治療するための医薬製剤 | |
| Minarik et al. | Taxol in combination with acute and low dose rate irradiation | |
| JP2014512391A5 (enExample) | ||
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| JP2016520057A (ja) | 癌の治療 | |
| KR19990014875A (ko) | 주효세포 조절을 위한 유전자 요법 | |
| Zhang et al. | Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy | |
| IL259512B1 (en) | Combination for effective treatment of metastatic cancer in patients | |
| Zhao et al. | Polymersome-enabled brain codelivery of STAT3 siRNA and CpG oligonucleotide boosts chemo-immunotherapy of malignant glioma | |
| JP2018530568A5 (enExample) | ||
| CN103861107A (zh) | 一种药物组合物及其用途 | |
| CN113440533A (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| KR101847252B1 (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 |